ArticleClinical and experimental pediatrics2025
Association between vitamin D polymorphisms and binding protein and COVID-19 risk and severity in children.
Article in Clinical and experimental pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitamin D receptor polymorphisms as predictors of pediatric infectious disease prevalence and outcome: an overview of available evidence.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe effects of genetic background on the biological effects of vitamin D on coronavirus disease 2019 (COVID-19) in children remain unclear. PURPOSE: This study aimed to explore the association between vitamin D-related genetic background and 25-hydroxyvitamin D status and COVID-19 occurrence and severity in children. Here we explored key genetic variants within the vitamin D pathway in pediatric COVID-19 patients in relation to circulating vitamin D binding protein (VDBP).
methodsSixty children aged 0-14 years with severe acute respiratory syndrome coronavirus 2 infection and 60 matched controls were genotyped for the vitamin D receptor (VDR) gene (FokI, BsmI, TaqI, ApaI), Gc gene of VDBP (rs7041, rs4588), and CYP27B1 promoter (rs10877012) single nucleotide polymorphisms by polymerase chain reaction and restriction fragment length polymorphism assay.
resultsThe FokI FF genotype was more frequently identified among COVID-19 patients than controls, among whom the TaqI TT genotype was prevalent (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.08-4.73; P=0.02; and OR, 0.29; 95% CI, 0.13-0.63; P=0.001, respectively). The Gc1F haplotype was significantly more represented in controls versus COVID-19 patients (OR, 0.39; 95% CI, 0.19-0.81; P=0.01). A 2.04-fold increased risk of COVID-19 was observed in the presence of the VDR FokI F allele (OR, 2.04; 95% CI, 1.14-3.64; P=0.01). A multivariate analysis revealed a significant association between the FokI FF genotype and disease severity (OR, 0.20; 95% CI, 0.04-0.83; P=0.02). Serum VDBP levels were similar between groups.
conclusionThe FF genotype of the VDR FokI polymorphism may be associated with COVID-19 and have a significant clinical impact on disease severity in children.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.